Oncology

From stratification to therapy

Metabolic pathways rather than organs

First universal digital twin in oncology paving the way for effective oncology based on pan-cancer stratification

More patients can benefit from your therapy

Pharmaceuticals companies : You have an anti-cancer targeted molecule in clinical phase 1, let’s work together to define the inclusion and exclusion criteria for phases 2 and 3, enabling your molecules to be brought to market.

Biotech companies : You want to develop a pan cancer drug. Let’s work together to find the good target

Our product range

Clinical trial optimization

Companion diagnostic

Stratification

Repositioning and repurposing of targeted therapies

New target pan cancer

They support us

• UPCité
• CNRS
• INCA
• Erganéo
• Paris Biotech Santé
• France 2030